Left Atrial Volume
0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Verona PharmaUK - London
1 programLeft Atrial Volume as Predictor for Arrhythmic Events and CRT ResponseN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Verona PharmaLeft Atrial Volume as Predictor for Arrhythmic Events and CRT Response
Clinical Trials (1)
Total enrollment: 230 patients across 1 trials
Left Atrial Volume as Predictor for Arrhythmic Events and CRT Response
Start: Apr 2016Est. completion: Feb 2020230 patients
N/AUnknown
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.